Best Hematology Oncology Center in Vizag

Dr Ramavath Dev

MBBS (JIPMER), MD-Medicine (AIIMS) DM-Medical Oncology - Gold Medal (AIIMS) ECMO- Medical Oncology Chief Consultant Medical Oncology Hemato-Oncology & BMT

ACADEMIC QUALIFICATIONS:

School Education	Nirmal English Residential School (1st – 5th class)
	Jawahar Navodaya Vidyalaya, Lepakshi (6th-10th class)
	Kakatiya Junior College, Hyderabad (11th-12th class)
M.B.B.S	JIPMER, Puducherry, India (July 2006 – December 2011)
MD Medicine	AIIMS, New Delhi, India (July 2012-June 2015)
DM Medical Oncology	DM Medical Oncology, AIIMS-New Delhi, India (Jan 2017- Dec 2019)
ECMO	Medical Oncology -2020
Current	Chief Consultant Medical Oncology , Hemato-Oncology & BMT, Medicover Cancer Institute, AP-INDIA

My Time Schedule

Mon - Sat:

5.00 pm - 9.00 pm

+919873742322

Dr. Ramavath Dev is currently working as chief Consultant Medical Oncology, Hemato-Oncology & BMT at Medicover Cancer Institute, Visakhapatnam, AP, India. He graduated MBBS from the premier Institute (JIPMER) in the year 2011. He has done his post-graduation (MD medicine) and super specialization (DM Medical Oncology) from All India Institute Of Medical Sciences (AIIMS-New Delhi).

Dr. Dev is specialized in management of various cancers in men, women and children. He is also well experienced in management of various blood cancers and Bone marrow transplantation. Dr Dev actively participates in Clinical Research and has been awarded Young Investigator Award by Society of Hemato-oncology (SOHO) in the year 2019 at Houston, Texas-USA for his contribution in acute leukemia research. He has also been awarded the "Young Investigator Award" by the International Society of Pediatric Oncology (SIOP) in the year 2019 at LYON-France for his research contribution to pediatric malignancies. Dr. Ramavath Dev was awarded Geeta Mittal Gold medal for his outstanding research contribution towards research in cancer care in the year 2020.

He had presented research papers on various cancers in many international & national conferences. He won many prizes for his poster presentations, research, and medical quiz activities.

Dr Dev is truly a service oriented oncologist. He is the founder & chairman of Cancer Cure Trust, which carries out various activities to eradicate cancer. He has organized many awareness and health camps in rural areas of Andhra Pradesh. He also travels a distance to help and treat underprivileged sectors of society.In recognition of his outstanding professional achievement and service to society, the Indian Achievers Forum has honored him with the “Young Achievers Award” for the year 2020. He was also awarded “Most distinguished Young researcher of Medical oncology & Hemato-oncology” by ‘India’s Best Doctors’ forum for the year 2021

He is currently heading the Department of Medical Oncology, Hemato-Oncology & BMT at Medicover Cancer Institute, Visakhapatnam.

AWARDS (Academic)

1.“Young Achievers Award”by IndianAchievers Forum in recognition of his “Outstanding professional achievement and contribution in Nation-building” for the year2020.
2.“Most distinguished Young researcher of Medicaloncology &Hemato-oncology”‘India’s Best Doctors’forum for the year 2021.
3.GitaMittalGoldMedal&BookPrize byAIIMS,NewDelhiinrecognitionofhisBest clinical research for the year 2019.
4.YoungInvestigatorAwardbySocietyOfHemato-oncology(SOHO)–Houston,Texas.
5.YoungInvestigatorAwardbyInternationalSocietyofPediatricOncology(SIOP)-Lyon, France.
6.Selectedfor Australia Asia – Pacific Clinical Oncology Research Development(ACORD)workshop2018,NSWAustralia.
7.Prathibha awardee for securing outstanding marks in class 11th and 12th.
8.Graduated MBBS degree in FIRST CLASS.
9.I was awarded certification of appreciation for my active participation in “Risk stratification of Coronary events” at JIPMER, Pondicherry.
10.Secured 1st place in State level and Regional level Hematology Quiz Competition during MD training (HEMATOCON).
11.Secured 1st placeat National Level Hematology Quiz competition during MD training (HEMATOCON).
12.Secured School First in Science subject during my 7th standard.
13.Secured School Second during my 10th class CBSE board examinations.

RESEARCH PAPERS:

1. Ramavath Dev. Naik, Sreenivas V, VishwajeetSingh,Ashwati S. Pillai, Deepa Dhawan,Sameer Bakhshi, et al: Olanzapine For Prevention Of Vomiting In Children And Adolescents Receiving Highly Emetogenic Chemotherapy (HEC): Investigator Initiated, Randomized, Open-Label Trial (PRaCTiCE TRIAL)I https://doi.org/10. 1200/JCO.20.00871(In Press)(Impact Factor 32.9)

2.Vinod Sharma,Ramavath Dev Naik,IlavarasiVanidassane et al: Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. (2020). New England Journal of Medicine, 382(7), 685–686. doi:10.1056/nejmc1916477

3.Ramavath Dev Naik, Atul Batra, Vineet G Gupta; Palbociclib and Fulvestrant in Breast Cancer. N Engl J Med. 2019 Feb 21;380(8):796–7.

4.Sra MS, Ganguly S, Naik RD, Sasi A, Sharma P, Giri RK, Abdul Rasheed A, Bakhshi S. Olanzapine cost-effectiveness in vomiting and nausea from highly emetogenic chemotherapy in children and adolescents. BMJ Support Palliat Care. 2024 Jan 8;13(e3):e1272-e1279. doi: 10.1136/spcare-2022-004069. PMID: 36813535.

5.High-dose chemotherapy followed by autologous stem cell transplant for multiple myeloma: Predictors of long-term outcome Kumar L, Ramavath Dev Naik,Kataria B, Tiwari A, Raj A, Chellapuram SK, Mookerjee A, Sahoo RK, Malik PS, Sharma A, Gupta R, Sharma Od, Biswas A, Kumar R, Thulkar S, for AIIMS Myeloma Group - Indian J Med Res

6.Induction Therapy with Novel Agents and Autologous Stem Cell Transplant Overcomes the Adverse Impact of Renal Impairment in Multiple Myeloma Lalit Kumar1, *, Santosh Kumar Chellapuram1, Ramavat Dev Naik1, Ankur Varshneya1, Satyajit Pawar1, Aparna Sharma1, Anjali Mookerjee1, Ranjit Kumar Sahoo1, Prabhat Singh Malik1, Atul Sharma1, Ritu Gupta2, Omdutta Sharma2, Ahitagni Biswas3, Rakesh Kumar4, Sanjay Thulkar5, Sauumyaranjan Mallick6

7.Ramavath Dev Naik, Gupta K, Soneja M, Elavarasi A, Sreenivas V, Sinha S. Sleep Quality and Quantity in Intensive Care Unit Patients: A Cross-sectional Study. Indian J Crit Care Med Peer-Rev Off Publ Indian Soc Crit Care Med. 2018 Jun;22(6):408–14.

8.Ramavath Dev Naik, Sanjeev Sinha, S.K Sharma; Sleep Disturbance in Critically Ill Patients at a Tertiary Care Centre: An Observational Study: Am Thorac Soc Int Conf Meet Abstr Am Thorac Soc Int Conf https://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2015.191.1_MeetingAbstracts.A5047

9.Ramavath Dev Naik, Ely E, A E. Chapter-009 Sedoanalgesia and Delirium. In: Textbook of Critical Care: Including Trauma and Emergency Care [Internet]. 1/e. Jaypee Brothers Medical Publishers (P) Ltd.; 2016. p. 116–30. Available from: http://www.jaypeedigital.com/Chapter/ChapterDetail/95805

10.Ramavath Dev Naik, Kumar L, Mittal A, Gupta VG, Patekar M, Malik PS, et al. Outcome of multiple myeloma patients with renal failure: A retrospective study. J Clin Oncol. 2018 May 20;36(15_suppl):e20026–e20026.

11.Patekar M, Kumar L, Sharma A, Gupta R, Vishnubhatla S, Ramavath Dev Naik, et al. Prospective evaluation of minimal residual disease in multiple myeloma following autologous stem cell transplantation(ASCT) and consolidation therapy. J Clin Oncol. 2018 May 20;36(15_suppl):e20033–e20033.

12.Ramavath Dev Naik (Expert Member) Consensus & Evidence-Based INOSA GUIDELINES (INdian initiative on Obstructive Sleep Apnea Guidelines)First Edition-2014 https://www.icmr.nic.in/sites/default/files/guidelines/INOSA_english.pdf

13.Lalit Kumar, Ramavath Dev Naik ; Multiple myeloma: High dose chemotherapy followed by autologous stem cell transplant: Predictors of long term outcome' Indian Journal of Medical Research (IJMR) (accepted awaiting publication)

14.Ilavarasi V, Ramavath Dev Naik, Atul Batra; Adjuvant Trastuzumab Emtasine In HER 2-Positive Breast Cancer: Take home points from KATHERINE Trial, The National Medical Journal Of India (NMJI) (accepted awaiting publication)

15.Expert Panel Member of First Indian Sleep Guidelines: Consensus and evidence-based Indian initiative on obstructive sleep apnea guidelines 2014 (first edition)

16.Unusual gastric metastasis in triple-negative (estrogen receptor/progesterone receptor/HER2neu negative) GATA-binding protein 3-positive breast cancer :Annie Kanchan Baa, Ramavath Dev Naik, Ilavarasi Vanidassane, Saurabh Arora, Shamim Ahmed Shamim, Saumyaranjan Mallick, Atul Batra, Indian Journal of Nuclear Medicine.

No areas of interest available.